Amgen Clinical Trial Pipeline — 100 Active Studies

Amgen pipeline at a glance (March 2026)

About the Amgen clinical program

Amgen's pipeline is defined by three breakthrough areas: targeted oncology (KRAS G12C inhibition with Lumakras/sotorasib, BiTE bispecific T-cell engagers led by Blincyto), cardiometabolic (Repatha/evolocumab for LDL lowering, olpasiran for Lp(a)), and inflammation/rare disease (Tezspire/tezepelumab for severe asthma, Otezla/apremilast). The KRAS franchise represents Amgen's most watched competitive program — Lumakras is the first approved KRAS inhibitor, and Amgen's pipeline of next-generation KRAS G12C inhibitors and KRAS combinations is closely tracked by the oncology community. Their BiTE platform (multiple CD19, BCMA, and other targets) continues generating new programs in hematology.

Key therapeutic areas

• Oncology (KRAS G12C, BiTE T-cell engagers)
• Cardiometabolic (PCSK9, Lp(a), HCM)
• Inflammation (TSLP, IL-5)
• Rare bone disease (denosumab)
• Hematology (BiTE, lymphoma)

Key pipeline programs

• Lumakras (sotorasib) — KRAS G12C inhibitor, NSCLC/CRC
• Blincyto (blinatumomab) — CD19xCD3 BiTE, ALL/NHL
• Repatha (evolocumab) — PCSK9 inhibitor, cardiovascular
• Tezspire (tezepelumab) — TSLP, severe asthma
• Olpasiran — siRNA, Lp(a) lowering
• AMG 193 — MTAP-deletion solid tumors

Top Amgen trial indications

Condition / Indication	Trials
["Atopic Dermatitis"]	4
["Thyroid Eye Disease"]	4
["Overweight", "Obesity"]	3
["Overweight and Obesity"]	2
["Diffuse Cutaneous Systemic Sclerosis", "Sclerosis, Systemic"]	2
["Osteogenesis Imperfecta"]	2
["Advanced Solid Tumors"]	2
["Metastatic Castration-resistant Prostate Cancer"]	2

Why monitor Amgen's clinical trial activity

Amgen's KRAS combination trials are the most watched oncology programs for anyone developing drugs in KRAS-altered cancers (particularly NSCLC, CRC, and pancreatic cancer). New Lumakras combination registrations signal competitive threat to programs developing SOS1, SHP2, or other KRAS-pathway inhibitors.

DataLookout monitors ClinicalTrials.gov daily and surfaces changes to Amgen's registered studies — new trial registrations, status transitions (e.g., "Not yet recruiting" → "Recruiting"), site additions, and protocol amendments. This is the intelligence layer that bridges the gap between quarterly investor calls and real-time pipeline developments.

How DataLookout tracks Amgen trials

• Sponsor normalization: Amgen may register trials under multiple legal entity names. DataLookout normalizes all related entities to a single canonical sponsor for complete pipeline coverage.
• Daily updates: ClinicalTrials.gov is queried each morning. New registrations and updates appear in that day's digest.
• Field-level change detection: Status changes, enrollment updates, and site additions are detected and surfaced — not just new registrations.
• Phase filtering: Focus on Phase 3 pivotal trials, Phase 2 proof-of-concept studies, or all phases for comprehensive coverage.
• Indication filtering: Combine sponsor monitoring with indication keywords to focus on the therapeutic areas relevant to your business.

Frequently asked questions

How many KRAS-related trials does Amgen currently have active?

Amgen's KRAS G12C program (Lumakras/sotorasib and next-generation inhibitors) is being tested in combination with MEK inhibitors, checkpoint inhibitors, and other targeted agents across NSCLC, colorectal cancer, and other KRAS G12C-altered tumors. DataLookout tracks all Amgen-sponsored KRAS trials in real time.

How many Amgen trials are currently recruiting?

Based on current ClinicalTrials.gov data, 45 Amgen-sponsored trials are actively recruiting patients globally across oncology, cardiometabolic, and inflammation programs.

Can DataLookout track Amgen BiTE programs separately?

Yes. You can filter Amgen-sponsored trials by mechanism keyword (e.g., 'bispecific T-cell engager', 'BiTE', 'blinatumomab') to monitor their T-cell engager pipeline specifically. Their CD20, BCMA, and solid tumor BiTE programs each have distinct competitive implications.